Brokers Offer Predictions for 89bio FY2025 Earnings

89bio, Inc. (NASDAQ:ETNB) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of 89bio in a research report issued on Wednesday, April 30th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings per share of ($3.35) for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for 89bio’s current full-year earnings is ($3.19) per share.

89bio (NASDAQ:ETNB) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.01. During the same period in the prior year, the company posted ($0.54) EPS.

A number of other research analysts have also recently issued reports on ETNB. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective (down from $29.00) on shares of 89bio in a report on Friday, February 28th. UBS Group lifted their price target on 89bio from $25.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Wolfe Research started coverage on 89bio in a research note on Tuesday, February 4th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 89bio in a research report on Thursday, April 24th. Finally, The Goldman Sachs Group assumed coverage on 89bio in a report on Friday, March 14th. They set a “neutral” rating and a $11.00 price target for the company. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $27.25.

89bio Stock Performance

NASDAQ ETNB opened at $8.73 on Friday. The company has a current ratio of 11.66, a quick ratio of 11.66 and a debt-to-equity ratio of 0.09. The company has a fifty day simple moving average of $7.38 and a 200 day simple moving average of $8.17. 89bio has a 12-month low of $4.16 and a 12-month high of $11.84. The company has a market cap of $1.27 billion, a P/E ratio of -3.00 and a beta of 1.25.

Insider Activity at 89bio

In other 89bio news, insider Quoc Le-Nguyen sold 15,329 shares of the company’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $5.95, for a total value of $91,207.55. Following the completion of the transaction, the insider now owns 328,323 shares in the company, valued at $1,953,521.85. This represents a 4.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On 89bio

A number of hedge funds and other institutional investors have recently made changes to their positions in ETNB. Avoro Capital Advisors LLC bought a new stake in 89bio in the fourth quarter worth about $32,062,000. Deep Track Capital LP raised its holdings in shares of 89bio by 134.2% in the 4th quarter. Deep Track Capital LP now owns 6,478,249 shares of the company’s stock worth $50,660,000 after purchasing an additional 3,711,737 shares during the period. Suvretta Capital Management LLC lifted its stake in 89bio by 27.7% in the fourth quarter. Suvretta Capital Management LLC now owns 10,202,696 shares of the company’s stock valued at $79,785,000 after purchasing an additional 2,211,052 shares during the last quarter. Emerald Advisers LLC bought a new position in 89bio during the first quarter valued at $11,273,000. Finally, Janus Henderson Group PLC increased its position in 89bio by 8.9% in the fourth quarter. Janus Henderson Group PLC now owns 16,514,056 shares of the company’s stock worth $129,177,000 after buying an additional 1,355,838 shares during the last quarter.

89bio Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.